

Date : _____/____ /

Mandatory Blood Glucose Monitoring following insulin and glucose to treat hyperkalaemia

Time sample taken	Monitoring schedule	Capillary glucose	K⁺ (mmol/L)
(24hr)		(mmol/L)	(
:	Baseline		
:	15 min		
:	30 min		
:	60 min*		
:	90 min		
:	2 hr		
:	3 hr		
:	4 hr		
:	6 hr		
:	8 hr		
:	12 hr		

Write in CAPITAL LETTERS or use addressograph
Surname:
First names:
H&C number:

DOB:

Advice on potassium monitoring

- 1. Insulin, glucose and salbutamol normally lower K⁺ by ~1.0mmol/L at 60 min
- 2. An urgent K⁺ level at 60 min post-treatment* informs acute monitoring, specifically:
 - Point of Care Test (POCT) analysers do not detect spurious hyperkalaemia (cell lysis) but provide reassurance in the emergency setting if reporting a K⁺<6.0mmol/L</p>
 - If relying on an urgent U&E lab sample for the 60 min K⁺ test, the result should ideally be available within 1 hr to inform management
 - A K⁺ <6.0mmol/L at 60 min on a POCT <u>or</u> lab test indicates a safe initial response. In such instances, check K⁺ again in 3 hr (i.e. 4 hr post treatment) on a lab sample, **not** a POCT (unless no alternative)
 - If K⁺ 6.0-6.4mmol/L at 60 min on a POCT then check on an urgent U&E lab sample. If K⁺ confirmed between 6.0-6.4mmol/L, send another urgent lab sample in 2 hr to determine the trend and discuss these results with senior member of staff

3. Tests beyond 4 hr are to detect rebound / recurrent hyperkalaemia. In acutely unwell patients (e.g. high NEWS, hypoxia) tests at 6, 8 and 12 hr are advisable; in stable cases tests at 8 and 24 hr may suffice. Discuss monitoring frequency with a senior member of staff.

If K+ ≥6.5mmol/L on ANY follow-up test (unless strongly suspecting a spurious result)

- Repeat an ABCDE assessment
- A
- Start a NEW monitoring form
- Complete steps 1-6 of the treatment algorithm
- Discuss with nephrology as by definition this is resistant or recurrent hyperkalaemia

MONITORING (Key Roles and Responsibilities)			
MEDICAL STAFF	NURSING STAFF		
Monitor and record potassium levels in the table provided and sign off on ECR	Monitor and Record blood glucose in the table		
	Contact the doctor looking after the patient or the on-call doctor if informed of any repeat K+ ≥6.5mmol/L.		

Management of Hyperkalaemia in Adult Inpatients



The **Regulation** and

Authority

Quality Improvement

- **REDUCE INTAKE**: Start a low potassium diet and stop any potassium supplements (e.g. Sando-K)
- **REVIEW KARDEX**: When safe to do so, hold RAAS inhibitors (Spironolactone, ACEi/ARB/Entresto), trimethoprim,
- co-trimoxazole, potassium sparing diuretics and NSAIDs. Treat any constipation. Exclude digoxin toxicity if indicated
- MANAGE AKI: If present, manage AKI as per GAIN AKI Guidelines (link to guidance via NIECR AKI e-Alert)
- CORRECT ACIDOSIS: If HCO3⁻ < 20mmol/L and K⁺ ≥6.0mmol/L discuss with Nephrology
- **EXCLUDE PSEUDOHYPERKALAEMIA**: Spurious hyperkalaemia results from cell lysis: e.g. delayed sample processing / platelet count>750/WCC>20). Exclude by repeating potassium on paired lithium heparin and clotted serum samples

*Within the appropriate clinical context consider Addison's and tissue breakdown (burns/tumour lysis/rhabdomyolysis).

INDICATIONS FOR SPECIALIST REFERRAL (NEPHROLOGY/CLIN. BIOCHEM)

- 1. Moderate hyperkalaemia (K⁺ ≥6.0mmol/L) and severely impaired renal function (creatinine >350umol/L)
- 2. Resistant or recurrent severe hyperkalaemia (K⁺ ≥6.5mmol/L despite treatment or recurring ≥6.5mmol/L within 24 hr)
- 3. Severe hyperkalaemia in a dialysis patient ($K^+ \ge 6.5$ mmol/L and on haemodialysis or peritoneal dialysis)
- 4. Moderate hyperkalaemia (K⁺ ≥6.0mmol/L) and significant metabolic acidosis (HCO3⁻ <20mmol/L)